PsychoGenics Inc.

PsychoGenics, a leader in preclinical neurobiology and major provider of CNS drug discovery solutions, works with pharmaceutical companies and not-for-profit organizations to validate targets and select compounds to advance into clinical trials. PsychoGenics is transforming CNS drug discovery by combining expertise in behavioral neurobiology with state-of-the-art technology to produce proprietary, high-throughput behavioral testing platforms that rapidly screens compound libraries for CNS activity. These platforms are being used with PsychoGenics’ battery of established behavioral tests to develop a pipeline of in-house and partnered drug candidates addressing such major CNS disorders as ADHD, anxiety, cognitive impairment, depression, eating disorders, pain, and psychosis/schizophrenia. PsychoGenics’ management is comprised of research and business development experts in the fields of neuro- and psychopharmacology, robotics, and bioinformatics. More than one-half of PsychoGenics' research staff have Ph.D.’s and the vast majority have extensive pharmaceutical industry experience. Research is conducted at PsychoGenics AAALAC compliant facilities in New York and Europe, under the direction of Dr. Paul McGonigle, CSO. The company's platform development is supported by an exclusive relationship with the Robotics Institute at Carnegie Mellon University.

Contact Details: 765 Old Saw Mill River Road Tarrytown New York 10591 United States of America Tel: 914-593-0640 Fax: 914-593-0645 Email: info@psychogenics.com WWW: www.psychogenics.com/

Loading...

Recent Publications by PsychoGenics Inc.:
Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic. Cognition is a complex set of processes, including attention, learning and...	4th October, 2008	PsychoGenics Inc, Cognitive Neurosciences, 765 Old Saw Mill River Road,	Curr Opin Investig Drugs. 2008 Jul;9(7):696-706.
Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Spinal muscular atrophy (SMA) is characterized by selective loss of...	18th July, 2008	PsychoGenics Inc., 765 Old Sawmill River Road, Tarrytown, NY 10591, USA.	Exp Neurol. 2008 Jul;212(1):29-43. Epub 2008 Mar 18. DOI Direct Link
Knock-in mouse models of Huntington's disease. Huntington's disease is an autosomal dominant neurodegenerative disorder...	21st January, 2006	PsychoGenics Inc., Tarrytown, New York 10591, USA.	NeuroRx. 2005 Jul;2(3):465-70.
Juvenile 5HT(1B) receptor knockout mice exhibit reduced pharmacological sensitivity to 5HT(1A) receptor activation. Serotonin is an important modulator of anxiety and thus drugs that act on...	16th December, 2004	PsychoGenics	Int J Dev Neurosci. 2004 Aug-Oct;22(5-6):405-13. DOI Direct Link

BioNews Results for PsychoGenics Inc.:
PsychoGenics Appoints John McCall, Ph.D. as Newest Member to its Scientific Advisory Board (SAB)	Pharma Live:  Aug 25 2008 12:42PM Matching: psychogenics inc

PsychoGenics Inc. Patents:
US Patent No.	Title
7269516	Systems and methods for monitoring behavior informatics
6837184	Programmable electronic maze for use in the assessment of animal behavior

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 207 times since April 2007, the link to the organisation's website has been followed 28 times

Recent Search Terms used to find this page: psychogenics | psychogenics profit | huntington s disease psychogenics | psychogenics inc AAALAC | PsychoGenics Inc. | psychogenics | psychogenics | psychogenics | Psychogenics Inc | psychogenics inc. | .

Search for more companies in Tarrytown

Search for more companies in New York

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for PsychoGenics Inc.